While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.

After Tacti-003’s controlled cohorts fail, Immutep plays up single-arm data in PD-L1 non-expressers.

Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.

The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.

Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.

A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.

Meanwhile, Bristol’s other competition in this disease looks set to come from China.

The group’s Kelun-partnered TROP2 ADC looks like a bargain, but Merck’s pipeline has big shoes to fill.